Skip to main content
. 2023 Aug 2;2(8):1093–1102. doi: 10.1016/j.gastha.2023.07.018

Table 2.

Incidence of Hepatocellular Carcinoma (%) After Liver Biopsy in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease (n = 1389)

Marker Category Number of patients (%) 1 y 3 y 5 y 10 y 15 y
aMAP score 0–50 620 (45.3) 0 0 0 0 0
50–60 545 (39.8) 0 0.7 1.6 5.7 8.8
60–100 203 (14.8) 0.5 3.5 9.5 21.9 24.7
FIB-4 index <1.30 589 (42.4) 0 0 0 0 0.6
1.30–2.67 469 (33.8) 0 0.5 0.8 1.6 5.1
>2.67 330 (23.8) 0.3 2.6 7.5 21.8 23.4
ALBI score ≤ −2.60 1126 (83.2) 0 0.7 1.1 3.3 4.2
> −2.60 228 (16.8) 0.5 1.7 7.6 15.2 24.7
Histological fibrosis F0–1 776 (55.9) 0.1 0.1 1.2 1.8 2.3
F2 394 (28.4) 0 1.0 1.5 5.7 8.5
F3 195 (14.0) 0 2.5 5.5 17.3 25.8
F4 24 (1.7) 0 5.6 5.6 24.4 24.4
NAS score 1–2 280 (20.2) 0 0 0.6 0.6 3.4
3–4 747 (53.8) 0.1 1.0 2.2 6.1 6.6
5–8 362 (26.1) 0 1.2 2.5 5.9 9.5